Validity and clinical utility of the aspartate aminotransferase–alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C …
E Giannini, D Risso, F Botta… - Archives of internal …, 2003 - jamanetwork.com
Background The aspartate aminotransferase–alanine aminotransferase ratio (AST/ALT
ratio) has been used to noninvasively assess the severity of disease in patients with chronic …
ratio) has been used to noninvasively assess the severity of disease in patients with chronic …
Dynamics of alanine aminotransferase during hepatitis C virus treatment
RM Ribeiro, J Layden-Almer, KA Powers, TJ Layden… - Hepatology, 2003 - Elsevier
Studies of the kinetics of hepatitis C virus (HCV) decline during interferon (IFN)-based
therapy have led to insights into treatment efficacy. However, the kinetics of serum alanine …
therapy have led to insights into treatment efficacy. However, the kinetics of serum alanine …
What is next in pharmacogenomics? Translating it to clinical practice
R Valdes Jr, MW Linder, SA Jortani - Pharmacogenomics, 2003 - Taylor & Francis
Pharmacogenomics (PG) holds promise for transforming medical therapeutics but the details
of how the promise will become reality are still vague. In this article, we focus on the role that …
of how the promise will become reality are still vague. In this article, we focus on the role that …
Laboratory approach to acute and chronic hepatitis.
DR Dufour - Medical Laboratory Observer (MLO), 2003 - search.ebscohost.com
Laboratory approach to acute and chmnic hepatitis Page 1 CEUs, see test on page 20.
LEARNING OBJECTIVES Upon completion of this article the reader will be able to: 1. Define …
LEARNING OBJECTIVES Upon completion of this article the reader will be able to: 1. Define …